Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Inclusion Criteria: * ECOG ≤ 1 * Willing to undergo tumor biopsies from injected and distal lesions * Must have two biopsy accessible lesions: * \* one lesion must be ≥10 mm and \<100 mm in longest diameter, accessible for repeated intratumoral (IT) injection and accessible for baseline and on-treatment biopsies. * a second (distal) lesion must be accessible for baseline and on-treatment biopsy and must be distinct from the injected lesion. * tumors encasing major vascular structures (i.e., carotid artery or tumors close to other vital organs), are not considered appropriate Exclusion Criteria: * Patients who require local palliative measures such as XRT or surgery * Symptomatic or untreated leptomeningeal disease. * Presence of symptomatic central nervous system (CNS) metastases * Impaired cardiac function or clinically significant cardiac disease * Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy. * Active infection requiring systemic antibiotic therapy. * Known history of Human Immunodeficiency Virus (HIV) infection. * Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV) * Malignant disease, other than that being treated in this study.